Format
Sort by

Send to

Choose Destination

Search results

Items: 3

1.

Role of 18F-FDG PET/CT in Posttreatment Evaluation of Anal Carcinoma.

Houard C, Pinaquy JB, Mesguich C, Henriques de Figueiredo B, Cazeau AL, Allard JB, Laharie H, Bordenave L, Fernandez P, Vendrely V.

J Nucl Med. 2017 Sep;58(9):1414-1420. doi: 10.2967/jnumed.116.185280. Epub 2017 Mar 9.

2.

Hodgkin lymphoma: is there really a need for interim and end-of-treatment FDG-PET evaluations? - Response to Adams & Kwee.

Mesguich C, Cazeau AL, Bouabdallah K, Hindié E.

Br J Haematol. 2018 Apr;181(1):124-125. doi: 10.1111/bjh.14494. Epub 2017 Jan 20. No abstract available.

PMID:
28106255
3.

Hodgkin lymphoma: a negative interim-PET cannot circumvent the need for end-of-treatment-PET evaluation.

Mesguich C, Cazeau AL, Bouabdallah K, Soubeyran P, Guyot M, Milpied N, Bordenave L, Hindié E.

Br J Haematol. 2016 Nov;175(4):652-660. doi: 10.1111/bjh.14292. Epub 2016 Aug 19.

PMID:
27539369

Supplemental Content

Loading ...
Support Center